Acrux (ACR) today announced positive results from the latest clinical trials of Nestorone® MDTS®, its unique contraceptive skin spray. The spray is designed to be a better choice for women using hormonal contraceptive pills or patches.
Acrux’s trials in Australia with 40 women tested a number of its skin spray formulations, applied to the forearm once a day over 14 days. The amount of hormones in the blood was measured once a day and every 4 hours on day 14.
Formulations containing Nestorone® and ethinyl estradiol successfully delivered therapeutic amounts of both hormones across the skin into the blood. All spray formulations were well tolerated, with no serious adverse events recorded.
The next step in the development of the contraceptive spray is expected to be a Phase 2 dose-ranging clinical trial before conducting Phase 3 global registration trials. Through its alliance with Orion Corporation, Acrux will have the capability to provide commercial manufacture and supply of Nestorone® MDTS®.
“These multi-dose, steady-state results are very exciting and represent the first extended trial of our unique combination contraceptive sprays”, commented Acrux CEO Richard Treagus. “The results with Nestorone®, together with our formulation work on other contraceptive progestins, now place Acrux in a strong position to make commercial progress in this very large market” he added.



